☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
novartis
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)
April 16, 2024
Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)
April 8, 2024
Novartis Reports Acquisition of IFM Due for the Development of STING Antagonist Program
March 14, 2024
Novartis Reports Updated Efficacy Data of Zolgensma from the P-IIIb (SMART) Study for the Treatment of Spinal Muscular Atrophy (SM...
March 4, 2024
Novartis Reports Acquisition of MorphoSys for ~$2.9B
February 6, 2024
Novartis Reports the Results for Scemblix (asciminib) in P-III Clinical Trial for the Treatment of Newly Diagnosed Chronic Myeloid...
January 8, 2024
Load more...
Back to Home